Catalog Number:
mUNO Peptide
UNO selectively targets Mannose Receptor (CD206/MRC1)-expressing Tumor-Associated Macrophages (TAMs), contributing to the suppression of tumor growth, angiogenesis, metastasis, and relapse. It was found that TAM-depleting agent (“OximUNO”) specifically targets CD206+ TAMs and demonstrated efficacy in a triple-negative breast cancer (TNBC) mouse model. Treatment with OximUNO reduced the progression of primary tumor lesions. The short linear peptide (CSPGAK, "mUNO") can be used for the delivery of molecular and nanoscale cargoes in M2 TAMs in vitro and the relevance of the peptide for in vivo targeting of early-stage primary breast tumors.
Lepland A, Malfanti A, Haljasorg U, Asciutto EK, Pickholz M, Bringas M, Peterson P, Teesalu T, Vicent MJ, Scodeller P. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice. Cancer Res Commun. 2022 Jun 28;2(6):533-551. doi: 10.1158/2767-9764.CRC-22-0043. PMID: 36923553; PMCID: PMC10010335.
  • 1 Units in Stock

Ask a Question


Add to Cart:
LifeTein LifeTein provides custom peptide synthesis service, recombinant proteins, peptides, cytokines, custom antibody service and custom protein service. LifeTein is the world leader in fast peptide synthesis service with lab facility located in New Jersey USA. LifeTein Peptide 100 Randolph Road, Suite 2D, Somerset USA New Jersey 08873
Copyright © 2024 Powered by LifeTein